Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)

Historic Non-Current Deffered Revenue for Maxcyte (MXCT) over the last 2 years, with Q3 2022 value amounting to $344600.0.

  • Maxcyte's Non-Current Deffered Revenue changed N/A to $344600.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $344600.0, marking a year-over-year change of. This contributed to the annual value of $450200.0 for FY2021, which is N/A changed from last year.
  • Latest data reveals that Maxcyte reported Non-Current Deffered Revenue of $344600.0 as of Q3 2022.
  • In the past 5 years, Maxcyte's Non-Current Deffered Revenue ranged from a high of $450200.0 in Q4 2021 and a low of $344600.0 during Q3 2022